



CorInnova has developed a minimally invasively-delivered soft robotic heart assist device, the world's first, to support heart function for treatment of Heart Failure. Innovative **EpicHeart™** is designed to overcome the limitations and complications of blood contact in order to eliminate 40% of the adverse events associated with FDA-cleared left ventricular assist devices (LVADs) and has the potential to promote heart recovery.

❑ FIRST COLLAPSIBLE AND SELF-EXPANDING SOFT ROBOTIC DEVICE FOR HEART FUNCTION SUPPORT WILL EXPAND TREATMENT OPTIONS TO MANY MORE PATIENTS.

One million U.S. and E.U. patients with end-stage Heart Failure have an extremely poor prognosis (40% two-year mortality), and treatment options are limited. Transplant is the preferred treatment because drug therapies are largely ineffective, but only about 4,500 hearts are available worldwide. Increasingly, LVADs are used to increase cardiac output for patients, but the use of the devices is limited to less than 10,000 per year because they require invasive surgery and contact the blood, risking blood clots and stroke as well as bleeding from blood damage and necessary anticoagulant therapy. **EpicHeart™** is a soft robotic direct cardiac compression device that can be collapsed into a one inch tube and delivered minimally invasively into the pericardial sac using proprietary self-expanding technology. The device increases cardiac output by gently squeezing the heart from the outside. Prior attempts at soft robotic assist devices required invasive surgery like LVADs. **EpicHeart™**'s minimally invasive implantation, plus lack of blood contact, may make the device suitable to help up to approximately 280,000 patients in the US and Europe who are too frail for existing assist devices.

❑ **DISRUPTIVE "NON-BLOOD-CONTACTING" TECHNOLOGY.** **EpicHeart™** is a breakthrough medical technology advancement. It is delivered minimally invasively, reducing hospital length of stay from 20-30 days to an estimated 4-6 days. The device does not contact the blood, eliminating risk of stroke and pump thrombosis, the need for anticoagulants, and the risk of gastrointestinal bleeding. It is biventricular, designed to treat those 15%+ of LVAD patients who develop right ventricular heart failure (RVHF). Moreover, device operation is non-obligatory: the device may be turned off safely without harming the patient. Overall, adverse events could be reduced 40% versus current assist devices.

❑ **RIGHT STRATEGY TO BREACH ENORMOUS MARKET OPPORTUNITY.** According to the *Global Left Ventricular Assist Device (LVAD) Market 2016-2020*, the worldwide market for LVADs is projected to grow at a CAGR of 13.19% through 2020, reaching sales of more than \$1 billion. CorInnova's less-invasive **EpicHeart™** device could potentially increase eligible patients by 4X, thus quadrupling the market to \$4+ billion.

❑ **WORLD-CLASS LEADERSHIP TEAM.** CEO William Altman is a Rhodes scholar, Harvard MBA, ex-McKinsey consultant, and successful serial entrepreneur. His team is exceptional and advisors include: the former SVP and Chief Regulatory Officer for Medtronic who also served as the FDA's Director of the Office of Device Evaluation; a CEO and former investment banker who raised \$2 billion for former companies; the inventor of the Thoratec PHP LVAD; a co-inventor of the TAXUS drug-eluting stent; and several KOLs in the field of heart failure.



"CorInnova's device will revolutionize the treatment of Heart Failure, saving countless lives."

William Altman
CEO, CorInnova, Inc.
Rhodes scholar, Harvard MBA, ex-McKinsey consultant, successful serial entrepreneur.



"CorInnova's device does not contact blood, eliminating risk of stroke and thrombosis, and need for anti-coagulants."

Boris Leschinsky
VP, Product Development, CorInnova, Inc.
Cardiac assist device authority; inventor of the Thoratec PHP next-gen LVAD.

CONTACTS & KEY INFORMATION

Headquarters	JLABS @ TMC 2450 Holcombe Blvd., Suite J Houston, TX 77021 (713) 530-1430
Website	www.corinnova.com
Ownership	Privately held
Funding	\$8.5 Million
Sector	Cardiac Assist Devices
Platform Mechanism	EpicHeart™ (preclinical): Collapsible thin-film pneumatically actuated soft robotic heart assist device that surrounds both ventricles of the heart; air inflates the device in synchrony with the heart and increases cardiac output by gently squeezing the heart.
PR Agency Contact	Ronald Trahan, APR Ronald Trahan Associates, Inc. +1 508-816-6730

LEADERSHIP TEAM AND ADVISERS

William Altman Chief Executive Officer
Boris Leschinsky VP, Product Dev; Inventor Thoratec PHP LVAD
John Criscione, M.D., Ph.D. Co-Founder, Chief Technical Officer
Clarice Motter Chief Financial Officer
Keith Svagerko VP, Administration & Business Development
William Abraham, M.D. Ohio State University School of Medicine
Susan Alpert, M.D., Ph.D. Fmr. Director, FDA Office of Device Evaluation
Dan Burkhoﬀ, M.D., Ph.D. Columbia University School of Medicine
Julie Gregory CEO, financier, raised \$2B for companies
William Hunter, M.D. Co-inventor of TAXUS drug-eluting stent
Ulrich Jorde, M.D. NY Presbyterian-Columbia Univ. Medical Ctr.
Dan Meyer M.D. Univ. of Texas Southwestern Medical Center